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Abstract Biomimetic techniques are used to deposit
coatings of calcium phosphate upon medical devices. The
procedure is conducted under near-physiological, or
“biomimetic”, conditions of temperature and pH primarily
to improve their biocompatibility and biodegradability of
the materials. The inorganic layers generated by biomi-
metic methods resemble bone mineral, and can be
degraded within a biological milieu.
The biomimetic coating technique involves the nuclea-
tion and growth of bone-like crystals upon a pretreated
substrate by immersing this in a supersaturated solution of
calcium phosphate under physiological conditions of
temperature (37°C) and pH (7.4). The method, originally
developed by Kokubo in 1990, has since undergone
improvement and reﬁnement by several groups of
investigators.
Biomimetic coatings are valuable in that they can serve
as a vehicle for the slow and sustained release of
osteogenic agents at the site of implantation. This attribute
is rendered possible by the near-physiological conditions
under which these coatings are prepared, which permits an
incorporation of bioactive agents into the inorganic crystal
latticework rather than their mere superﬁcial adsorption
onto preformed layers. In addition, the biomimetic coating
technique can be applied to implants of an organic as well
as of an inorganic nature and to those with irregular surface
geometries, which is not possible using conventional
methodologies.
Keywords biomimetic, biomineralization, osteoinduc-
tion, osteogenic agent, tissue engineering
1 Introduction
The mineralization of biological tissues is a well-regulated
process, which often occurs within a matrix of proteins and
proteoglycans. The protein molecules may either comple-
tely envelop, or be themselves enveloped by, the mineral
crystals. These organic molecules are essential not only for
the initial deposition of mineral crystals, but also for their
subsequent growth, orientation and organization. How,
precisely, the proteins become sequestered by mineral
crystals, determine their properties and participate in the
crystallization process are questions that have been
addressed, but not satisfactorily answered to date.
Anionic polypeptides and proteins that have been
extracted from calciﬁed tissues, such as nacre, are known
to act as seeds for the growth of calcite or aragonite when
they are attached to a substratum. Several groups of
investigators have endeavoured to imitate this biological
mineralization process by immersing polymeric substrates
within metastable solutions of the inorganic components.
And in one such attempt, calcium carbonate was success-
fully imprinted upon a surface of acidic acrylate. On the
basis of nucleation studies involving Langmuir and self-
assembled monolayers, crystal growth under the afore-
mentioned in-vitro conditions has been attributed to a
lattice match between the organic and the inorganic phases.
In orthopaedic and dental implantology, novel tools and
techniques are being sought to improve the healing of bony
tissue and osseointegration. Numerous attempts have been
made to enhance the osteoconductivity of titanium
prostheses. These include modiﬁcations in their surface
properties and coating with a layer of calcium phosphate.
Hydroxyapatite and related calcium phosphates are
known to be biocompatible and osteoconductive [1,2].
Hydroxyapatite ceramics have been widely employed in
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orthopaedics for nearly 20 years. They are relatively cheap,
non-toxic, minimally resorbed, of acceptable compressive
strength, attach well to hard tissues and conduct bone
apposition. The major drawback of hydroxyapatite cera-
mics is their low tensile strength [3–6]. Until recently,
layers of calcium phosphate were deposited upon the
surfaces of metal implants under physical conditions that
were highly unphysiological. The methods employed have
been various and include plasma spraying, high-velocity
oxygen-fuel spraying, electrophoretic deposition, sol-gel
deposition, hot isostatic pressing, frit enamelling, ion-
assisted deposition, pulsed-laser deposition, electrochemi-
cal deposition and sputter coating [1,6–16].
Hydroxyapatite is the most important representative of
the bioactive calcium-phosphate ceramics. There is abun-
dant evidence in the literature that sintered hydroxyapatite
is well incorporated into living bone and that it does not
undergo any signiﬁcant biodegradation once it has become
bonded to osseous tissue (a feature that may be
disadvantageous as well as advantageous) [5,6,17,18].
Although the static mechanical strength of sintered
hydroxyapatite is comparable to that of cortical bone,
this material is prone to fatigue failure under conditions of
high-tensile loading, which renders it unsuitable for
applications in load-bearing situations. Titanium pros-
theses that have been coated with plasma-sprayed layers of
hydroxyapatite have been used with promising results in
joint reconstruction. The plasma-spraying technique,
however, is conducted at extremely high temperatures
(> 1000°C). The mineral layers generated are composed of
large, partially molten hydroxyapatite particles, which are
not only prone to delamination but are also poorly
degraded in a biological milieu.
The technique whereby such mineral layers are
produced has recently undergone a revolutionary change
[19–21], which has had profound consequences for their
potential to serve as drug-carrier systems. Hitherto, as
aforementioned, calcium-phosphate layers were deposited
upon the surfaces of metal implants under highly
unphysiological physical conditions, which precluded the
incorporation of bioactive agents. These agents could only
be adsorbed, superﬁcially, upon preformed layers. Such
superﬁcially adsorbed molecules are released too rapidly
within a biological milieu to be effective in their
osteoinductive capacity. Now, it is possible to deposit
calcium-phosphate layers under near-physiological condi-
tions of temperature and pH by the so-called biomimetic
technique, during which process bioactive agents can be
co-precipitated [22–24]. Since these molecules are inte-
grated into the inorganic latticework, they are released
gradually in vivo as the layer undergoes degradation. This
feature enhances the capacity of these coatings to act as a
carrier system for osteogenic agents, for example, bone
morphogenetic proteins (BMPs) and the growth and
differentiation factors (GDFs).
2 Biomimetic mineral coatings
Biomimetics, which literally means the mimicry of
biology, is a branch of science in which biologists and
engineers jointly endeavour to produce “bioinspired”
materials that can be used for tissue engineering. This
broad new ﬁeld has ancient roots. The replacement of
bodily parts dates back at least 2500 years to the time when
the Etruscans substituted missing teeth with artiﬁcial ones
carved from the bones of oxen. The ﬁrst recorded use of
dental amalgam to repair decayed teeth was in China in the
year 659 AD. As human life expectancy continues to
increase, the need for better coping with diseased,
damaged or destroyed bodily components has heightened.
2.1 Preparation technique
Several years ago, attempts were made to coat medical
devices with layers of calcium phosphate under more
physiological or “biomimetic” conditions of temperature
and pH [2,19,20,22,23,25], primarily to improve their
biocompatibility and biodegradability. The inorganic
layers generated by biomimetic methods are comparable
to bone mineral, whereas those produced by conventional
methods are composed of large, partially molten hydroxy-
apatite particles, which are not only prone to delamination
but are also poorly degraded within a biological milieu.
The biomimetic coating technique involves the nuclea-
tion and growth of bone-like crystals upon a pretreated
implant by immersing this within a supersaturated solution
of calcium phosphate under physiological conditions of
temperature (37°C) and pH (7.4). The method, originally
developed by Kokubo et al. in 1990 [19], has since been
improved and reﬁned by several groups of investigators
[23,26–32].
The implant is ﬁrst immersed within ﬁve-times-
concentrated simulated body ﬂuid under high-nucleation
conditions, viz., in the presence of Mg2+ [(7.5 mol/L)
see Table 1], to inhibit crystal growth, for 24 h at 37°C. A
thin (< 3-μm-thick), dense and amorphous layer of
calcium phosphate is thereby uniformly deposited upon
the implant surface, and this serves as a seeding substratum
for the subsequent growth of a substantial (30- to 50-μm-
thick) crystalline latticework. The latter is prepared by
immersing the coated implant within a supersaturated
Table 1 Millimolar compositions of human blood plasma (HBP),
simulated body ﬂuid (SBF), ﬁve-times-concentrated SBF (SBF5) and
supersaturated calcium-phosphate solution (CPS)
Na+ Mg2+ Ca2+ Cl
–
HPO2 –4 HCO
–
3
HBP 142.0 1.5 2.5 103.0 1.0 27.0
SBF 146.7 1.5 2.5 147.8 1.0 4.2
SBF5 733.5 7.5 12.5 740.0 5.0 21.0
CPS 140.4 0 3.1 142.9 1.86 0
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solution of calcium phosphate [(pH 7.4) Table 1] for 48 h at
37°C. Under these conditions, the crystalline latticework is
composed of octacalcium phosphate (Fig. 1).
The crystal structure of the inorganic latticework can be
modiﬁed by changing the ionic composition of the coating
solution, by increasing its temperature, or by prolonging
the duration of the coating period.
The biomimetic coating process is simple to perform and
cost-effective, and can be applied even to heat-sensitive,
non-conductive porous materials of large dimensions with
complex surface geometries. An additional advantage of
the biomimetic method is that biologically active mole-
cules, such as osteogenic agents, can be coprecipitated
with the inorganic components. As a consequence, the
proteins are truly incorporated into the crystal latticeworks
and not merely deposited upon their surfaces. In forming
an integral part of the calcium-phosphate coatings, the
protein molecules are liberated not in a single burst (as
when superﬁcially adsorbed), but gradually, which bodes
well for an enduring osteogenic effect at the implantation
site. The disadvantage of such coatings is that they are of
low cohesiveness and are degradable, both in vitro and in
vivo, and adhere poorly to the underlying substrate.
However, in a clinical situation, their biodegradability
could be advantageous, particularly if they are serving as a
vehicle for drug delivery.
2.2 Characterization of mineral coatings
2.2.1 Coating thickness
The thickness of coatings (up to 100 μm) can be measured
in situ using a magnetic induction probe (Electrophysik
minitest 2100, Germany).
2.2.2 Fourier-transform infrared spectroscopy
In preparation for Fourier-transform infrared spectroscopy,
the coatings are peeled away from the carriers and then
mixed with potassium bromide (0.6–0.8 mg of sample
material per 280 mg of potassium bromide). By means of
this technique, the types of chemical bonds existing within
the coatings can be established.
2.2.3 Scanning electron microscopy and energy-dispersive
X-ray spectroscopy
Prior to examination in a scanning electron microscope, the
coated carriers are sputtered with carbon particles to a
thickness of 12–16 nm. Scanning electron microscopy
yields information on the geometry of the crystals of which
the coatings are composed, whereas energy-dispersive X-
ray spectroscopy furnishes data on their chemical structure.
2.2.4 Typical results achieved using the standard
biomimetic coating process
Mineral layers are typically 10–50 µm in thickness.
Scanning electron micrographs reveal coatings of octacal-
cium phosphate to be composed of thin, plate-like crystals
(Fig. 1); those of carbonated apatite have an amorphous or
a nano-crystalline appearance (Fig. 2).
Fourier-transform infrared spectroscopy discloses coat-
ings of carbonated apatite to manifest two prominent
absorption bands at 1410 and 1460 cm–1. Two C –O bands
stemming fromCO2 –3 groups appear at 1470 and 1425 cm
–1,
P –O bands from PO3 –4 groups at 1115, 1042, 970, 610 and
570 cm–1, and P –OH bands from HPO2 –4 groups at 920
and 870 cm–1. Coatings of octacalcium phosphate are
characterized by bands at 906 and 852 cm–1 [29].
2.3 Biological functionalization of mineral coatings
Although biomimetic calcium-phosphate coatings improve
the osteoconductivity of metal implants, they do not render
them osteoinductive, a feature that is required to
expedite the osteogenic process and to accelerate implant
Fig. 1 Scanning electron micrographs of an octacalcium-phosphate coating at (a) low and (b) high magniﬁcations
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integration. This property can be conferred by the
introduction of an osteogenic agent [33–37]. Using
conventional coating methods, osteogenic agents can be
deposited only superﬁcially upon preformed coatings,
either by adsorption [33,38–40], by binding to biofunc-
tional proteins [41], or by chemical treatment [42]. The
disadvantage of this mode of attachment is that the
biologically active molecules are released rapidly upon
exposure to a physiological environment. Consequently,
their osteogenic effects are short-lived. Using the biomi-
metic technique, osteogenic agents can be incorporated
into the crystal latticework of the coatings. Consequently,
they are released more slowly over a longer time-span.
3 Biomimetic mineral coatings as a
delivery vehicle for osteogenic agents
The advent of the biomimetic coating technique has
broadened the potential of calcium-phosphate layers to
serve as a carrier system for osteogenic agents, thereby
rendering them osteoinductive as well as osteoconductive.
Granted this facility, investigators must select an appro-
priate osteogenic agent.
Members of the transforming growth factor superfamily
(TGF-βs), such as GDFs and especially BMPs, probably
represent the most promising candidates for this purpose.
Interest in this latter group of agents dates back to 1964. In
this year, Urist [43] demonstrated that demineralized, dried
and pulverized bone could stimulate the formation of
osseous tissue at an ectopic site (muscle) in rabbits. The
osteogenic fraction of the bone matrix was later isolated
and subjected to amino-acid sequencing. This analysis
revealed BMPs to be structurally similar to TGF-βs, and
they are now classed as a subgroup of this superfamily
[44–47]. More than 15 of the 30 odd members have been
isolated and synthesized by recombinant DNA technology
[48–50].
Interest in BMPs obviously preceded the advent of the
biomimetic coating technology, and various materials have
thus already served as their carriers. These include
collagen, synthetic and natural ceramics, demineralized
bone matrix and polyglycolic acid [47,51–56]. Human
recombinant BMP-2 used in conjunction with each of these
carrier systems is released in two kinetically distinct
phases: an initial rapid one of a few hours’ duration and a
second slower one spanning several weeks. Collagen
retains the largest fraction of BMP-2 during the initial
phase and synthetic hydroxyapatite particles the smallest
(10%). The other carriers retain between 30% and 50% of
their load during this phase. With the exception of
synthetic hydroxyapatite, the mineral-based carriers retain
the largest fraction of BMP-2 during the second phase,
thereby reﬂecting their high afﬁnity for this agent.
However, none of the materials serve as an optimal drug-
delivery system.
The potential of biomimetic calcium-phosphate coatings
to serve as a carrier system for BMP-2 is now being
investigated by our group [57–59]. The drug has
been successfully co-precipitated with the inorganic
components and, thus incorporated, retains its biological
activity in vitro [58,59]. Experiments using an ectopic
(subcutaneous) model for bone formation in rats have
revealed BMP-2 thus borne to be osteogenically potent.
Furthermore, bone-forming activities are sustained for a
considerable period of time, which indicates that BMP-2 is
indeed released gradually (as anticipated) and not in a
single rapid burst [57].
Instead of incorporating BMP-2 itself into a carrier
system, the drug could be substituted by a plasmid
containing the gene for the agent. The rationale behind
such an undertaking would be that whilst a protein is
ultimately degraded, a gene would become incorporated
into a host cell and remain active for a longer period [60–
62]. The gene for BMP-2 has been delivered to orthotopic
sites in rats and dogs via viral and non-viral carriers
[48,63]; it has not yet been incorporated into biomimetic
implant coatings.
Fig. 2 Scanning electron micrographs of (a) an amorphous and (b) a nano-crystalline layer of carbonated apatite
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4 In-vitro and in-vivo testing of the
osteogenic potential of BMP-2-functionalized
biomimetic coatings
4.1 In-vitro testing
Titanium-alloy implants were coated biomimetically
with a layer of calcium phosphate into which different
amounts of BMP-2 were incorporated (1–3 µg/implant).
The osteogenic potency of BMP-2 thus incorporated was
assessed by monitoring the alkaline-phosphate activity of
rat bone-marrow stromal cells that were cultured directly
upon the coated implants. BMP-2 that was incorporated
into the calcium-phosphate coatings was more potent in
stimulating the alkaline-phosphatase activity of bone-
marrow stromal cells that were cultured thereupon than
was the freely suspended drug in stimulating the alkaline-
phosphatase activity of the same cell population that was
cultured on a plastic surface. Hence, the osteogenic
potency of BMP-2 is not only retained but enhanced by
its biomimetic incorporation into a calcium-phosphate
layer, probably by virtue of a localized concentration
effect.
4.2 Ectopic model in rats
We investigated the potential of BMP-2-functionalized
calcium-phosphate coatings to induce and sustain bone
formation at an ectopic (subcutaneous) site in rats over a
period of 5 weeks. For this purpose, one experimental and
three control groups were established: titanium-alloy
implants bearing a co-precipitated layer of calcium
phosphate and BMP-2 (experimental group); naked
titanium-alloy discs (negative control for the effects of a
calcium-phosphate layer and of BMP-2); titanium-alloy
discs bearing a layer of calcium phosphate (negative
control for the effects of BMP-2); and titanium-alloy discs
bearing a layer of calcium phosphate and superﬁcially
adsorbed BMP-2 (positive control for superﬁcially
adsorbed BMP-2). Six implants per group were implanted
subcutaneously in the dorsal region of rats, two per animal.
Samples were retrieved at 7-day intervals over a period of 5
weeks for histological and histomorphometric analyses.
Ectopic bone formation occurred only in the experimental
group of animals (Fig. 3). Bone tissue ﬁrst became
apparent 2 weeks after implantation and thereafter was
deposited continually until the end of the 5-week
monitoring period. Ossiﬁcation occurred intramembra-
nously (directly), there being virtually no evidence of an
endochondral mechanism having been followed. The total
volume of bone formed increased signiﬁcantly (p < 0.005)
from 5.8 mm3 per implant after the second week to 10.2
mm3 per implant after the third, when the net daily rate of
bone formation was the highest (0.8 mm3 per implant per
day). Bone tissue was deposited not only upon the implant
surfaces but also at some distance therefrom, maximally at
Fig. 3 (a) Light micrographs of a vertically-sectioned titanium-alloy disc bearing a calcium-phosphate coating, 5 weeks after
implantation at a subcutaneous site in a rat (low, intermediate and high magniﬁcations). No osseous tissue has been deposited. (b) Light
micrographs of a vertically-sectioned titanium-alloy disc bearing a BMP-2-functionalized calcium-phosphate coating, 5 weeks after
implantation at a subcutaneous site in a rat (low, intermediate and high magniﬁcations). The upper image reveals the surface of the implant
to be covered with osseous tissue. In the middle image, osteoblasts are seen to align the bone surface in an epithelium-like manner. The
lower panel reveals bone-marrow tissue to contact the coating directly.
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340 µm by the end of the third week. This distance had
decreased to 200 µm by the end of the ﬁfth week,
indicating that bone remodelling processes were underway,
which would be a normal occurrence under physiological
conditions. The biomimetic coating was degraded gradu-
ally during the course of the 5-week monitoring period, by
the end of which time, one third of its volume remained.
The implication is, that one third of the initially
incorporated amount of BMP-2 (1.7 µg per implant)
likewise remained, and that bone formation could have
continued for several more weeks after the end of the
experimental period. The ﬁndings of this study demon-
strate that when BMP-2 is incorporated biomimetically
into calcium-phosphate coatings at a low pharmacological
dose, it is capable not only of inducing the formation of
bone at an ectopic site but also of sustaining osteogenic
activity for a considerable period of time.
4.3 Orthotopic model in miniature pigs
To clarify the potential beneﬁcial and adverse effects of
BMP-2 on the osteoconductivity of titanium-alloy
implants, we considered two basic types of surface: a sand-
blasted, acid-etched one and a sand-blasted, acid-etched
one coated with a layer of calcium phosphate. These two
surfaces served as the base-line controls. In the ﬁrst
category, BMP-2 was adsorbed directly onto the metal
surface; in the second, it was either adsorbed onto,
incorporated into, or incorporated into and adsorbed onto
the calcium-phosphate coating. The implants were inserted
into the partially edentulous maxillae of adult Goettingen
miniature pigs. The neoformation of bone both along the
implant surface and up to a distance of 175 µm therefrom
(the immediate peri-implant space) was monitored quanti-
tatively 1, 2, and 3 weeks after surgery, viz., during the
early phase of healing when any interference with the
osteoconductivity of the implants would be apparent.
Our ﬁndings revealed the osteoconductivity of the
implants to be greatly inﬂuenced by BMP-2 and its mode
of delivery. The net volume of bone deposited within the
immediate vicinity of the coated implants (up to 175 µm
therefrom) could be increased by the presence of BMP-2
during the ﬁrst two postoperative weeks, but was
decreased by its presence during the third. Bone coverage
of the coated implants was lowered by the presence of
BMP-2 at each weekly juncture. The net volume of bone
deposited both directly upon and within the immediate
vicinity of uncoated implants was lowered by the presence
of BMP-2 at each time-point. In general, implant
osteoconductivity was most severely compromised when
BMP-2 was present as an adsorbed depot (subject to burst-
release kinetics), and less so when it was delivered via a
slow-release system (incorporated into a calcium-
phosphate coating).
Data relating to the degradation of implant coatings are
summarized in Table 2. Coatings bearing incorporated and
adsorbed BMP-2 underwent the most extensive degrada-
tion during the 3-week monitoring period, followed by
those bearing only an incorporated depot of the drug.
Coatings bearing no BMP-2 underwent the least degrada-
tion during the 3-week monitoring period, followed by
those bearing only an adsorbed depot of the drug.
5 Biological functionalization of
biomimetic mineral coatings
That calcium-phosphate layers are biocompatible and
osteoconductive is well known. Indeed, it was for these
attributes that this type of coating was chosen to act as a
carrier for BMP-2. Although BMP-2 is itself osteoinduc-
tive, its osteogenic potency is markedly enhanced after
incorporation into biomimetic calcium-phosphate coatings
[58]. This ﬁnding is accounted for by the drug’s slow rate
of release from these coatings over a protracted period of
time. BMP-2 is liberated gradually because it forms an
integral part of the inorganic latticework. BMP-2 that has
been deposited superﬁcially upon the surfaces of pre-
formed calcium-phosphate coatings is released in a single
rapid burst. Since the drug is highly water-soluble, it
diffuses away from the implantation site too quickly to
exert an osteogenic effect [57]. The forces governing
protein adsorption onto the surface of a preformed
calcium-phosphate coating are believed to be chieﬂy
electrostatic in nature [64], but the mechanisms underlying
the incorporation of protein molecules during their co-
precipitation with calcium phosphate are more complex
and poorly understood. Protein molecules possibly
participate in the formation of the three-dimensional
crystal latticework, or at least inﬂuence its growth. They
may act as tied molecules, in which case they would be
effectively bonded, or serve as seeds for crystallization and
possibly inﬂuence the number of nucleation sites generated
[65,66]. Protein molecules may also be aggregated and
penetrated by mineral ions during the formation of a
coating. Although bovine serum albumin inﬂuences the
structure of the calcium-phosphate latticework into which
it is incorporated, BMP-2 does not have this effect. Hence,
the mechanism of incorporation may be different in each
case. However, the presence of incorporated BMP-2 does
Table 2 Changes in coating thickness during the 3-week monitoring
period [Mean values (n = 6) are represented together with the standard
error of the mean]
Mode of BMP-2 loading Coating thickness /μm
[initial coating thickness = (54.78.73) µm]
Incorporated Adsorbed Week 1 Week 2 Week 3
+ – 22.264.26 2.581.36 1.080.45
– + 45.534.36 16.825.45 13.354.17
+ + 14.632.46 6.522.82 0.460.2
– – 52.001.83 27.727.69 15.313.14
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inﬂuence the physical properties of biomimetic coatings.
In vivo, proteins are known to strengthen mineralized
tissue and to stabilize its mineral contents. And in our
studies, the rate of release of calcium ions from biomimetic
coatings was indeed slowed down by the presence of
incorporated BMP-2, which may improve the coating’s
attachment to the underlying titanium-alloy implant.
Indeed, coatings that are functionalized with BMP-2
have been shown to be mechanically more cohesive than
unfunctionalized ones. BMP-2 that has been incorporated
into the body of the inorganic latticework possibly
reinforces the coating by surrounding the brittle calcium-
phosphate crystals, in analogy to the situation occurring in
dental enamel. This property of mechanical cohesiveness is
important during the surgical implantation procedure,
which generates high shear forces that could rupture the
coatings. That the coated implants furnished a mechani-
cally stable environment in vivo was evidenced by the
ﬁnding that ectopic bone formation in rats occurred by
intramembranous growth. In previous studies that have
made use of this model, ossiﬁcation has followed a
predominantly endchondral course, which requires a less
stable mechanical environment. Our own studies with the
model [67] also yielded evidence of the high biocompati-
bility of the BMP-2-functionalized coatings, in that bone-
marrow tissue was sometimes observed to contact these
directly, without intervening bone (see Fig. 3). Bone-
marrow tissue contains immunocompetent cells, which are
very sensitive to foreign material. Dental implants bearing
BMP-2-functionalized calcium-phosphate coatings were
more rapidly osseointegrated at an orthotopic site in adult
miniature pigs than were uncoated ones [68].
6 Conclusions
BMP-2 can be incorporated in a dose-dependent manner
into biomimetic calcium-phosphate coatings that are
deposited upon titanium-alloy implants. The incorporated
BMP-2 is released gradually (over a period of several
weeks) into the surrounding milieu wherein it retains its
biological activity. At an ectopic site in rats, BMP-2 is
released from the coatings and induces the formation of
bone not only upon the implant surface but also within its
immediate surroundings. At an orthotopic dental site in
adult miniature pigs, coatings bearing an incorporated
depot of BMP-2 enhance implant osseointegration.
Biomimetic mineral coatings are valuable in that they
can serve as a vehicle for the slow, sustained release of an
osteogenic agent at an implantation site. This facility
relates to the near-physiological conditions under which
the mineral coatings are prepared, which permits the
incorporation of biological agents into the inorganic crystal
latticework rather than their mere superﬁcial adsorption
upon preformed layers. Furthermore, the biomimetic
coating technique can be applied to implants of an organic
as well as of an inorganic nature and to those with irregular
surface geometries, which is not possible using methodo-
logies.
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